1
PHIL 434 Week 3 Reflection Assignment
Actual Exam 2026/2027 | Prenatal Genetic
Testing Ethics | West Coast University | Pass
Guaranteed - A+ Graded
Section 1: Foundational Concepts in Prenatal Genetic Testing
3 Questions | Cognitive Level: Recall & Comprehension
Question 1
Describe the main types of prenatal genetic testing currently available, including the timing,
purpose, and conditions detected by each. Include at least four different types of tests in your
response.
Key Concepts to Address:
• Carrier screening (preconception or early pregnancy): Identifies if parents carry genes
for recessive disorders (cystic fibrosis, Tay-Sachs, sickle cell, spinal muscular atrophy)
• Maternal serum screening (first and second trimester): Measures substances in maternal
blood to assess risk of neural tube defects, Down syndrome, trisomy 18
• NIPT/cell-free DNA testing (from 10 weeks gestation): Analyzes fetal DNA in maternal
blood for trisomies 21, 18, 13 and sex chromosome abnormalities
• Chorionic villus sampling (CVS) (10-13 weeks): Placental tissue sampling for
chromosomal and genetic disorders; carries ~0.5-1% miscarriage risk
• Amniocentesis (15-20 weeks): Amniotic fluid sampling for chromosomal and genetic
disorders, neural tube defects; carries ~0.1-0.3% miscarriage risk
• Ultrasound/NT scan (11-14 weeks): Anatomical screening for structural abnormalities,
nuchal translucency measurement
Sample Response Elements:
,2
"Prenatal genetic testing encompasses several categories performed at different gestational ages
with varying purposes. Carrier screening is ideally performed preconception or early in
pregnancy to identify if prospective parents carry autosomal recessive conditions such as cystic
fibrosis, Tay-Sachs disease, or sickle cell anemia. This information informs reproductive risk but
does not diagnose the fetus. First and second-trimester maternal serum screening measures
biochemical markers in maternal blood (PAPP-A, hCG, AFP, estriol, inhibin A) to calculate risk
for neural tube defects and chromosomal aneuploidies including Down syndrome and trisomy
18. Non-invasive prenatal testing (NIPT), available from 10 weeks gestation, analyzes cell-free
fetal DNA in maternal circulation with >99% sensitivity for detecting trisomies 21, 18, and 13, as
well as sex chromosome abnormalities. While highly accurate, NIPT remains a screening test
with rare false positives. Diagnostic procedures include chorionic villus sampling (CVS)
performed at 10-13 weeks via transcervical or transabdominal placental biopsy, and
amniocentesis at 15-20 weeks involving amniotic fluid aspiration. These provide definitive
karyotype or microarray results but carry procedure-related miscarriage risks of approximately
0.5% and 0.1-0.3% respectively. Understanding these distinctions is essential for appropriate
patient counseling."
Grading Considerations:
• Excellent (9-10 points): Accurately describes four+ test types with correct timing,
purpose, and conditions; demonstrates understanding of screening vs. diagnostic
distinction
• Competent (8 points): Describes four test types with minor errors in timing or purpose
• Developing (7 points): Describes three or fewer tests or contains significant factual
errors
Question 2
Explain the difference between screening tests and diagnostic tests in the context of prenatal
genetic testing. Why is this distinction critically important for patient counseling and informed
consent?
Key Concepts to Address:
• Screening tests assess risk/probability, not definitive diagnosis (NIPT, maternal serum
screening, nuchal translucency)
• Diagnostic tests provide definitive answers with high accuracy (CVS, amniocentesis,
detailed ultrasound anomalies)
• Screening limitations: False positives (anxiety, unnecessary invasive procedures), false
negatives (false reassurance)
, 3
• Diagnostic limitations: Invasive nature, procedure risks (miscarriage), cannot detect all
conditions
• Counseling implications: Managing expectations, appropriate next steps, avoiding
deterministic language
• Informed consent necessity: Patients must understand they may receive uncertain or
alarming information requiring further testing
Sample Response Elements:
"The distinction between screening and diagnostic testing represents a fundamental concept in
prenatal care with profound ethical implications. Screening tests—including maternal serum
screening, NIPT, and nuchal translucency ultrasound—function as probability assessments,
calculating risk ratios rather than providing binary answers. For example, a 'positive' NIPT for
trisomy 21 indicates increased probability (positive predictive value varies by condition and
maternal age, roughly 90-95% for Down syndrome) but requires diagnostic confirmation. These
tests generate false positives (screening positive when fetus is unaffected) and false negatives
(screening negative when fetus is affected), with implications for parental anxiety and decision-
making. Diagnostic tests—CVS, amniocentesis, and certain detailed ultrasound findings—offer
definitive chromosomal or genetic diagnosis with near 100% accuracy for detectable conditions.
However, they involve invasive procedures carrying miscarriage risks and cannot identify all
genetic disorders or structural abnormalities. This distinction is ethically crucial because
misunderstanding leads to decision-making based on probabilities rather than certainties.
Patients receiving positive screening results may make irreversible decisions (pregnancy
termination) without confirmatory testing, or experience severe anxiety awaiting diagnosis.
Conversely, negative screening results may provide false reassurance. Effective counseling
requires explaining sensitivity, specificity, positive predictive value, and the cascade of decisions
each result triggers. Providers must use precise language—'increased risk' versus 'diagnosis'—to
support truly informed consent and autonomous decision-making."
Grading Considerations:
• Excellent (9-10 points): Clearly distinguishes screening vs. diagnostic with statistical
concepts; explains multiple counseling implications
• Competent (8 points): Identifies basic distinction with some discussion of counseling
importance
• Developing (7 points): Vague distinction or misses critical implications for patient care
Question 3
PHIL 434 Week 3 Reflection Assignment
Actual Exam 2026/2027 | Prenatal Genetic
Testing Ethics | West Coast University | Pass
Guaranteed - A+ Graded
Section 1: Foundational Concepts in Prenatal Genetic Testing
3 Questions | Cognitive Level: Recall & Comprehension
Question 1
Describe the main types of prenatal genetic testing currently available, including the timing,
purpose, and conditions detected by each. Include at least four different types of tests in your
response.
Key Concepts to Address:
• Carrier screening (preconception or early pregnancy): Identifies if parents carry genes
for recessive disorders (cystic fibrosis, Tay-Sachs, sickle cell, spinal muscular atrophy)
• Maternal serum screening (first and second trimester): Measures substances in maternal
blood to assess risk of neural tube defects, Down syndrome, trisomy 18
• NIPT/cell-free DNA testing (from 10 weeks gestation): Analyzes fetal DNA in maternal
blood for trisomies 21, 18, 13 and sex chromosome abnormalities
• Chorionic villus sampling (CVS) (10-13 weeks): Placental tissue sampling for
chromosomal and genetic disorders; carries ~0.5-1% miscarriage risk
• Amniocentesis (15-20 weeks): Amniotic fluid sampling for chromosomal and genetic
disorders, neural tube defects; carries ~0.1-0.3% miscarriage risk
• Ultrasound/NT scan (11-14 weeks): Anatomical screening for structural abnormalities,
nuchal translucency measurement
Sample Response Elements:
,2
"Prenatal genetic testing encompasses several categories performed at different gestational ages
with varying purposes. Carrier screening is ideally performed preconception or early in
pregnancy to identify if prospective parents carry autosomal recessive conditions such as cystic
fibrosis, Tay-Sachs disease, or sickle cell anemia. This information informs reproductive risk but
does not diagnose the fetus. First and second-trimester maternal serum screening measures
biochemical markers in maternal blood (PAPP-A, hCG, AFP, estriol, inhibin A) to calculate risk
for neural tube defects and chromosomal aneuploidies including Down syndrome and trisomy
18. Non-invasive prenatal testing (NIPT), available from 10 weeks gestation, analyzes cell-free
fetal DNA in maternal circulation with >99% sensitivity for detecting trisomies 21, 18, and 13, as
well as sex chromosome abnormalities. While highly accurate, NIPT remains a screening test
with rare false positives. Diagnostic procedures include chorionic villus sampling (CVS)
performed at 10-13 weeks via transcervical or transabdominal placental biopsy, and
amniocentesis at 15-20 weeks involving amniotic fluid aspiration. These provide definitive
karyotype or microarray results but carry procedure-related miscarriage risks of approximately
0.5% and 0.1-0.3% respectively. Understanding these distinctions is essential for appropriate
patient counseling."
Grading Considerations:
• Excellent (9-10 points): Accurately describes four+ test types with correct timing,
purpose, and conditions; demonstrates understanding of screening vs. diagnostic
distinction
• Competent (8 points): Describes four test types with minor errors in timing or purpose
• Developing (7 points): Describes three or fewer tests or contains significant factual
errors
Question 2
Explain the difference between screening tests and diagnostic tests in the context of prenatal
genetic testing. Why is this distinction critically important for patient counseling and informed
consent?
Key Concepts to Address:
• Screening tests assess risk/probability, not definitive diagnosis (NIPT, maternal serum
screening, nuchal translucency)
• Diagnostic tests provide definitive answers with high accuracy (CVS, amniocentesis,
detailed ultrasound anomalies)
• Screening limitations: False positives (anxiety, unnecessary invasive procedures), false
negatives (false reassurance)
, 3
• Diagnostic limitations: Invasive nature, procedure risks (miscarriage), cannot detect all
conditions
• Counseling implications: Managing expectations, appropriate next steps, avoiding
deterministic language
• Informed consent necessity: Patients must understand they may receive uncertain or
alarming information requiring further testing
Sample Response Elements:
"The distinction between screening and diagnostic testing represents a fundamental concept in
prenatal care with profound ethical implications. Screening tests—including maternal serum
screening, NIPT, and nuchal translucency ultrasound—function as probability assessments,
calculating risk ratios rather than providing binary answers. For example, a 'positive' NIPT for
trisomy 21 indicates increased probability (positive predictive value varies by condition and
maternal age, roughly 90-95% for Down syndrome) but requires diagnostic confirmation. These
tests generate false positives (screening positive when fetus is unaffected) and false negatives
(screening negative when fetus is affected), with implications for parental anxiety and decision-
making. Diagnostic tests—CVS, amniocentesis, and certain detailed ultrasound findings—offer
definitive chromosomal or genetic diagnosis with near 100% accuracy for detectable conditions.
However, they involve invasive procedures carrying miscarriage risks and cannot identify all
genetic disorders or structural abnormalities. This distinction is ethically crucial because
misunderstanding leads to decision-making based on probabilities rather than certainties.
Patients receiving positive screening results may make irreversible decisions (pregnancy
termination) without confirmatory testing, or experience severe anxiety awaiting diagnosis.
Conversely, negative screening results may provide false reassurance. Effective counseling
requires explaining sensitivity, specificity, positive predictive value, and the cascade of decisions
each result triggers. Providers must use precise language—'increased risk' versus 'diagnosis'—to
support truly informed consent and autonomous decision-making."
Grading Considerations:
• Excellent (9-10 points): Clearly distinguishes screening vs. diagnostic with statistical
concepts; explains multiple counseling implications
• Competent (8 points): Identifies basic distinction with some discussion of counseling
importance
• Developing (7 points): Vague distinction or misses critical implications for patient care
Question 3
